Donahue Stephanie, Quinn Davin K, Cukor Daniel, Kimmel Paul L
The Rogosin Institute, New York, NY.
Department of Psychiatry and Behavioral Sciences, University of New Mexico School of Medicine, Albuquerque, NM.
Semin Nephrol. 2021 Nov;41(6):516-525. doi: 10.1016/j.semnephrol.2021.10.004.
Anxiety is common in patients with chronic kidney disease, but in its extreme expressions, anxiety can also be a complicating comorbid psychiatric illness. There is only a small literature base on anxiety disorders in patients with renal disease, and many of the studies are not sufficiently specific about which anxiety disorders are being studied. Larger epidemiological studies are required to delineate the incidence, prevalence, and outcomes associated with the varied anxiety disorders. In addition, the impact of the co-occurrence of anxiety with other chronic psychiatric or medical problems, needs further study. Anxiety is a clinical condition that warrants treatment, primarily due to its association with mortality in end-stage renal disease patients, and its negative impact on perceived quality of life. Therapeutic options for patients with anxiety and kidney disease include both pharmacologic and nonpharmacologic approaches. Current treatment strategies for anxiety specific to patients with renal disease are provided.
焦虑在慢性肾病患者中很常见，但在其极端表现形式下，焦虑也可能是一种复杂的共病性精神疾病。关于肾病患者焦虑症的文献基础较少，而且许多研究对于所研究的焦虑症类型不够明确。需要进行更大规模的流行病学研究来描述与各种焦虑症相关的发病率、患病率和转归。此外，焦虑与其他慢性精神或医学问题同时出现的影响也需要进一步研究。焦虑是一种需要治疗的临床病症，主要是因为它与终末期肾病患者的死亡率相关，以及对感知生活质量有负面影响。焦虑和肾病患者的治疗选择包括药物和非药物方法。本文提供了针对肾病患者的焦虑症当前治疗策略。
